Takeda Pharmaceutical (TKPYY) Stock Down After U.S. Federal Jury Imposes $6 Billion In Damages

NEW YORK (TheStreet) -- Shares of Takeda Pharmaceutical Co.  (TKPYY) are down 4.52% to $22.25

The Japan-based company said it would fight $6 billion in punitive damages imposed by a U.S. federal jury in a case alleging the drugmaker concealed cancer risks associated with its Actos diabetes drug, Reuters reports.

Eli Lilly and Co, (LLY), Takeda's co-defendant in the case, was ordered to pay $3 billion in punitive damages.

Must Read: Warren Buffett's 10 Favorite Growth Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TKPYY Chart

TKPYY data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

The Next Target in Biotech Land

The Next Target in Biotech Land

The Next Target in Biotech Land

The Next Target in Biotech Land

4 Biotech Names That Could Be M&A Targets

4 Biotech Names That Could Be M&A Targets

Takeda Acquires Ariad Pharmaceuticals in $5.2 Billion Deal

Takeda Acquires Ariad Pharmaceuticals in $5.2 Billion Deal

A Very Happy New Year for Investors in Japan

A Very Happy New Year for Investors in Japan